Nemetschek SE (0FDT)
London Exchange · UK · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 74.95 |
|---|---|
| 52-week range | 50.50 – 105.90 |
| Return, 1 month / 3 months | +20.8% / +37.4% |
| Return, 1 year / 3 years | −27.8% / +21.0% |
| Trend | Uptrend |
| RSI (14) | 75 |
| Volatility (1 year) | 47.2% |
| Worst drawdown (1 year) | -49.6% |
| Average daily value traded | 2.09M EUR |
| Dividend yield | 0.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Nemetschek SE is a German software company based in Munich that develops design and building information modelling software for the architecture, engineering and construction industries. Its brands provide tools for architectural design, structural analysis, building information modelling, facilities management and visualisation, along with software for media and entertainment creators. Customers include architects, engineers, construction firms and creative professionals who use the products to plan, model and document buildings and other projects.
The shares are listed on the London Exchange in UK under the code 0FDT, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Nemetschek SE (0FDT) trades on the London Exchange in UK. It last closed at EUR 74.95 on 22 October 2026.
Its price-based Market X-Ray is 47 out of 100 (a weak price profile), ranking 2,231 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 27.8% and over the last three months it rose 37.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 56 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 16.7% | ||
| From 52-week high | -28.6% | ||
| Momentum | 60 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 37.4% | ||
| 6-month return | 13.7% | ||
| 12-month return, skipping the last month | -40.2% | ||
| Stability (higher is calmer) | 26 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 47.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -49.6% | ||
| Liquidity | 60 · Fair | Moderate trading activity. | |
| Average daily value traded | 2.09M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 27 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.9% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +3.9% |
|---|---|
| 1 month | +20.8% |
| 3 months | +37.4% |
| 6 months | +13.7% |
| 1 year | −27.8% |
| 3 years | +21.0% |
| 5 years | −21.5% |
Signals
| 50-day / 200-day average | 64.83 / 64.22 |
|---|---|
| Golden / death cross (60 days) | Golden, 1 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.58 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 May 2026 | EUR 0.6800 |
| 21 May 2025 | EUR 0.5500 |
| 24 May 2024 | EUR 0.4800 |
| 24 May 2023 | EUR 0.4500 |
| 13 May 2022 | EUR 0.3900 |
| 13 May 2021 | EUR 0.3000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.